Nucleus RadioPharma to receive Lu-177 under agreement with SHINE
November 21, 2023, 12:00PMNuclear News
Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.
Tags:
Share: